Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page
- Check2 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe 403 error block was removed, allowing the page to display the study details rather than an error page.SummaryDifference0.5%

- Check23 days agoChange DetectedThe page now displays a 403 Forbidden error, blocking access to the study record. Visitors see the site’s error view instead of the NCT02788474 details.SummaryDifference17%

- Check44 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, indicating a minor release. This does not modify the information presented to users.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study record adds an NIH grant/contract attribution for 2015 under Other Study ID Numbers. It also introduces a Related Info section and sponsor-related entries, including Boehringer Ingelheim and a Helpful Links Provided by label.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a newer page build. The visible content remains unchanged.SummaryDifference0.0%

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.